# Arcus Biosciences (RCUS) — News

RCUS · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/rcus/news

## Recent headlines

- [PTC Industries - Raises 18 bln rupees through qualified institutions placement](https://www.ainvest.com/news/ptc-industries-raises-18-bln-rupees-qualified-institutions-placement-2610) — AInvest Wire, Oct 13, 2026
  PTC Industries has raised ₹18 billion through a qualified institutional placement (QIP), a move aimed at strengthening its capital base and supporting ongoing expansion initiatives. The placement was oversubscribed, reflecting strong investor confidence in the company’s strategic direction and…
- [Aequs signs long-term supply pacts with Safran](https://www.ainvest.com/news/aequs-signs-long-term-supply-pacts-safran-2610) — AInvest Wire, Oct 12, 2026
- [Standard Chartered PLC - Standard Chartered launches RLUSD custody and joins planned collateral integration with Ripple and Lmax Group](https://www.ainvest.com/news/standard-chartered-plc-standard-chartered-launches-rlusd-custody-joins-planned-collateral-integration-ripple-lmax-group-2610) — AInvest Wire, Oct 12, 2026
  Standard Chartered PLC has announced the launch of custody services for Ripple USD (RLUSD), a stablecoin backed by U.S. dollars and designed for institutional use. This move aligns with the bank’s broader strategy to expand its digital asset offerings and support the integration of traditional…
- [Arcus Biosciences, Inc.: TD Cowen initiates coverage with buy rating](https://www.ainvest.com/news/arcus-biosciences-td-cowen-initiates-coverage-buy-rating-2609) — AInvest Wire, Sep 16, 2026
  TD Cowen has initiated coverage on Arcus Biosciences, Inc. (NYSE: RCUS) with a "Buy" rating, signaling positive outlook on the biotechnology company. The move comes amid ongoing developments involving the company, which recently received undisclosed regulatory or corporate news. Arcus Biosciences,…
- [Arcus Biosciences, Inc.: Truist Securities raises target price to $40 from $35](https://www.ainvest.com/news/arcus-biosciences-truist-securities-raises-target-price-40-35-2609) — AInvest Wire, Sep 8, 2026
  Truist Securities has revised its price target for Arcus Biosciences, Inc. (NASDAQ: RCUS), raising it to $40 from $35, reflecting updated expectations for the biotechnology company’s near-term prospects. The adjustment follows recent developments in Arcus’ clinical pipeline and evolving market…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).